The US Patent and Trademark Office (USPTO) has granted Patent No 8,288,160 entitled “Activation Induced Deaminase (AID)” to AnaptysBio, Inc.  

This patent, the 16th issuance in AnaptysBio’s intellectual property portfolio, broadly covers the use of in vitro somatic hypermutation (SHM) in eukaryotic cells for the discovery and optimization of antibodies.  Previously issued patents within AnaptysBio’s intellectual property portfolio are directed to the use of somatic hypermutation in prokaryotic cells and various lymphoid cell lines.  

AnaptysBio has exclusive rights to the aforementioned patent, which is based upon the seminal work by Dr. Michael Neuberger in the field of somatic hypermutation and  is owned by the Medical Research Council.  Dr. Neuberger has been a  key  member of AnaptysBio’s scientific advisory board since the Company’s inception.

AnaptysBio’s intellectual property portfolio protects the Company’s proprietary antibody discovery and optimization platform technology, known as SHM-XEL.  As the first antibody platform to replicate SHM  in vitro,  SHM-XEL overcomes limitations of prior technologies by  coupling mammalian cell-based fully human antibody libraries with in vitro SHM to rapidly generate therapeutic lead candidates selected foraffinity, function, cross-reactivity, epitope diversity and expression.  

“SHM-XEL is a powerful methodology that surpasses prior techniques for therapeutic antibody discovery and maturation,” said Hamza Suria, AnaptysBio’s president and chief executive officer. “The speed and versatility of SHM-XEL has enabled AnaptysBio to rapidly develop therapeutic antibodies with unique functionality and robust biophysical properties.”

Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization.